Tokyo – The rollout of recently approved breast cancer and diabetes treatments from international pharmaceutical companies has faced significant delays in Japan, as ongoing negotiations over pricing persist, underscoring concerns among foreign drugmakers about the country’s stringent state-regulated pricing framework.
